3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Small Cell Lung Carcinoma
3
Lung Neoplasms
2
Urinary Bladder Neoplasms
1
Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
pembrolizumab
26
Nivolumab
10
Docetaxel
8
avelumab
7
atezolizumab
7
Gemcitabine
7
Carboplatin
6
Trastuzumab
5
Ipilimumab
5
Radiosurgery
4
Psychiatric Rehabilitation
4
Immunoglobulin G
4
Early Intervention, Educational
4
Cyclophosphamide
4
fludarabine
3
durvalumab
3
cemiplimab
3
Taxes
3
Radiotherapy
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Disulfides
3
Counseling
3
Cisplatin
3
Blood Specimen Collection
3
Biopsy
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
zimberelimab
2
utomilumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Tiragolumab
×
Thoracic
×
Clear all
NCT05259319
2023-10-17
IMMUNOs-SBRT
Centre Georges Francois Leclerc
Phase 1
Unknown
92 enrolled